Report
Thomas J. Schiessle
EUR 160.00 For Business Accounts Only

Mehr Klarheit über DC-Vaccine bei MDG1 im weiteren Verlaufe des Januar 2020

Sehr enttäuscht haben Inverstoren auf die auf der 61. ASH-Jahrestagung in Orlando, USA, vorgestellten 12-Monats-Interim-Behandlungsdaten der PhI/II mit Medigenes dendritischen Zell-(DC)-Impfstoff zur Behandlung von akuter myeloischer Leukämie (AML), reagiert. Obgleich das reifste Projekt bei MDG1 nach einer 12-monatigen Behandlungszeit eine Gesamtüberlebensrate 89 % (18 von 20 Patienten, 95 % Konfidenzintervall: 61 bis 97 %) und die Rate des progressionsfreien Überlebens von 60 % zeigte. U.E. aussichtsreiche KPI´s.

Im Januar 2020 werden die Topline-Daten veröffentlicht, was mehr Klarheit bringen dürfte - Halten.

Underlying
Medigene AG

Medigene is a biopharmaceutical company that focuses on the research and development of drugs to treat cancer and autoimmune diseases. Co.'s segments are: marketed products and drug candidates. Co.'s marketed products segment consists of the drug Veregen®, which is an ointment for the treatment of external genital warts. Co.'s drug candidates segment consists of: EndoTAG®-1, which is for the indication pancreatic cancer and triple-negative breast cancer; RhuDex®, which is a modifying agent for the oral treatment of autoimmune diseases; and adeno-associated virus-like particles, which provides potential as prophylactic and therapeutic vaccines, for example, against cancer and infections.

Provider
EQUITS GmbH
EQUITS GmbH

EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Analysts
Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts